HC Wainwright & Co. reiterates Buy rating on Sophia Genetics, $14 price target

HC Wainwright & Co. reiterated a Buy rating and $14 price target for Sophia Genetics, implying 88.9% upside from the Oct 9 close. The firm cited strong U.S. revenue growth potential and innovative oncology applications as key drivers.

Original reporting
Published Oct 12, 2026, 11:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. reiterates Buy rating on Sophia Genetics, $14 price target — source image
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

The reiterated Buy and $14 target suggest a bullish outlook, potentially prompting short‑term buying.

02

Market read

New analyst rating provides a fresh catalyst for SOPH, likely influencing its near‑term price action.

03

What to watch

Potential regulatory hurdles and competition from larger diagnostics firms.

Relevance 6/10Novelty 6/10Timing: today

Background

Analyst note from HC Wainwright highlighting revenue growth and oncology applications for SOPH.

Company-level read

Ticker impact

$SOPHBullishHigh confidence
Context

HC Wainwright reiterated a Buy rating on SOPH with a $14 price target, implying 88.9% upside.

Expected impact

likely upward pressure as investors price in the new target

Evidence & confidence

The fresh Buy rating and near‑double price target provide a concrete catalyst for short‑term demand.

Market effects

May boost sentiment for genomics and AI‑driven diagnostics peers.

Limited to biotech/health‑tech investors, primarily US and European markets.

Modest; affects niche biotech segment rather than broad indices.

Counterpoint

Target may be overly optimistic given early‑stage revenue base.

Key entities

  • HC Wainwright & Co.

    Equity research firm issuing the rating.

  • Sophia Genetics

    Genomics data analytics firm listed on Nasdaq (SOPH).

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September